(French) ADN tumoral circulant dans le sang : un nouveau biomarqueur du cancer

Sorry, this press release is only available in French.

Press release – Inserm press room (French) ADN tumoral circulant dans le sang : un nouveau biomarqueur du cancer Link : https://presse.inserm.fr/en/french-adn-tumoral-circulant-dans-le-sang-un-nouveau-biomarqueur-du-cancer/1831/

Other contents In the same category :

Cancer Voir tout

Early Environmental Exposures and Child Respiratory Health: the Exposome Reveals its Preliminary Results

A team of researchers from Inserm, CNRS, Université Grenoble Alpes and Barcelona Institute for Global Health has shown that prenatal and postnatal exposure to various chemical pollutants is linked to decreased respiratory function in children. These results, based on the concept of ...

Research shows that treatment with growth hormone in children who have recovered from cancer does not increase the risk of a second tumor.

Les données d'une nouvelle étude confirment que le traitement par hormone de croissance suite à une radiothérapie chez les enfants qui présentent un déficit de cette hormone n’augmente pas le risque de survenue d’un second cancer. ...

(French) ADN tumoral circulant dans le sang : un nouveau biomarqueur du cancer

Other contents In the same category :

Early Environmental Exposures and Child Respiratory Health: the Exposome Reveals its Preliminary Results

Research shows that treatment with growth hormone in children who have recovered from cancer does not increase the risk of a second tumor.

Launch of a European clinical trial against COVID-19

Les vaccins à ARNm susceptibles de modifier notre génome, vraiment ?

New Antibiotics Developed by Inserm and Université de Rennes 1

The BCG vaccine against COVID-19 – really?